Literature DB >> 25596270

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Philippe Moreau1, Halyna Pylypenko2, Sebastian Grosicki3, Ievgenii Karamanesht4, Xavier Leleu5, Grigoriy Rekhtman6, Zvenyslava Masliak7, Pawel Robak8, Dixie-Lee Esseltine9, Huaibao Feng10, William Deraedt11, Helgi van de Velde11, Bertrand Arnulf12.   

Abstract

Entities:  

Keywords:  MM patients; intravenous bortezomib; relapsed multiple myeloma; renally impaired

Mesh：

Substances：

Year:  2015        PMID： 25596270      PMCID： PMC4420234          DOI： 10.3324/haematol.2014.118182

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.

Authors:  Anne Lok; Julie Mocquard; Jessie Bourcier; Laurence Redelsperger; Antoine Bonnet; Cecile Chauvin; Patrick Thomaré; Beatrice Mahé; Cyrille Touzeau; Philippe Moreau
Journal:  Haematologica       Date:  2014-02-14       Impact factor: 9.941

2.  Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.

Authors:  V Eleutherakis-Papaiakovou; A Bamias; D Gika; A Simeonidis; A Pouli; A Anagnostopoulos; E Michali; T Economopoulos; K Zervas; M A Dimopoulos
Journal:  Leuk Lymphoma       Date:  2007-02

3.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

4.  Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Authors:  Heinz Ludwig; Zdenek Adam; Roman Hajek; Richard Greil; Elena Tóthová; Felix Keil; Eva Maria Autzinger; Josef Thaler; Heinz Gisslinger; Alois Lang; Miklós Egyed; Irene Womastek; Niklas Zojer
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

5.  Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.

Authors:  Maria Roussou; Efstathios Kastritis; Dimitrios Christoulas; Magdalini Migkou; Maria Gavriatopoulou; Irini Grapsa; Erasmia Psimenou; Dimitra Gika; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Leuk Res       Date:  2010-05-26       Impact factor: 3.156

Review 6.  Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.

Authors:  Asher A Chanan-Khan; Jesús F San Miguel; Sundar Jagannath; Heinz Ludwig; Meletios A Dimopoulos
Journal:  Clin Cancer Res       Date:  2012-02-10       Impact factor: 12.531

7.  Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

Authors:  J F San-Miguel; P G Richardson; P Sonneveld; M W Schuster; D Irwin; E A Stadtmauer; T Facon; J-L Harousseau; D Ben-Yehuda; S Lonial; H Goldschmidt; D Reece; J Bladé; M Boccadoro; J D Cavenagh; R Neuwirth; A L Boral; D-L Esseltine; K C Anderson
Journal:  Leukemia       Date:  2008-01-17       Impact factor: 11.528

8.  Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

Authors:  Meletios A Dimopoulos; Maria Roussou; Maria Gavriatopoulou; Flora Zagouri; Magdalini Migkou; Charis Matsouka; Despina Barbarousi; Dimitrios Christoulas; Erasmia Primenou; Irini Grapsa; Evangelos Terpos; Efstathios Kastritis
Journal:  Clin Lymphoma Myeloma       Date:  2009-08

9.  VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

Authors:  Meletios A Dimopoulos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Ofer Shpilberg; Efstathios Kastritis; Martin Kropff; Maria T Petrucci; Michel Delforge; Julia Alexeeva; Rik Schots; Tamás Masszi; Maria-Victoria Mateos; William Deraedt; Kevin Liu; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

10.  Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.

Authors:  Joan Bladé; Pieter Sonneveld; Jesús F San Miguel; Heather J Sutherland; Roman Hajek; Arnon Nagler; Andrew Spencer; Tadeusz Robak; M Teresa Cibeira; Sen H Zhuang; Jean-Luc Harousseau; Robert Z Orlowski
Journal:  Clin Lymphoma Myeloma       Date:  2008-12
View more
  13 in total

Review 1.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

Review 2.  Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Authors:  Jonathan J Hogan; Brendan M Weiss
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-14       Impact factor: 8.237

Review 3.  Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Authors:  David Dingli; Sikander Ailawadhi; P Leif Bergsagel; Francis K Buadi; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Wilson I Gonsalves; Susan R Hayman; Prashant Kapoor; Taxiarchis Kourelis; Shaji K Kumar; Robert A Kyle; Martha Q Lacy; Nelson Leung; Yi Lin; John A Lust; Joseph R Mikhael; Craig B Reeder; Vivek Roy; Stephen J Russell; Taimur Sher; A Keith Stewart; Rahma Warsame; Stephen R Zeldenrust; S Vincent Rajkumar; Asher A Chanan Khan
Journal:  Mayo Clin Proc       Date:  2017-03-11       Impact factor: 7.616

4.  Supportive care in multiple myeloma: Current practices and advances.

Authors:  Teresa S Miceli; Wilson I Gonsalves; Francis K Buadi
Journal:  Cancer Treat Res Commun       Date:  2021-10-09

Review 5.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Authors:  Jing-Fen Jin; Ling-Ling Zhu; Meng Chen; Hui-Min Xu; Hua-Fen Wang; Xiu-Qin Feng; Xiu-Ping Zhu; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

Review 6.  Proteasome-associated deubiquitinases and cancer.

Authors:  Arjan Mofers; Paola Pellegrini; Stig Linder; Pádraig D'Arcy
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

Review 7.  Update on the optimal use of bortezomib in the treatment of multiple myeloma.

Authors:  Meera Mohan; Aasiya Matin; Faith E Davies
Journal:  Cancer Manag Res       Date:  2017-03-02       Impact factor: 3.989

8.  A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.

Authors:  Neeraj Gupta; Michael J Hanley; R Donald Harvey; Ashraf Badros; Brea Lipe; Vishal Kukreti; Jesus Berdeja; Huyuan Yang; Ai-Min Hui; Mark Qian; Xiaoquan Zhang; Karthik Venkatakrishnan; Ajai Chari
Journal:  Br J Haematol       Date:  2016-05-16       Impact factor: 6.998

Review 9.  Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Authors:  Barbara Muz; Rachel Nicole Ghazarian; Monica Ou; Micah John Luderer; Hubert Daniel Kusdono; Abdel Kareem Azab
Journal:  Drug Des Devel Ther       Date:  2016-01-11       Impact factor: 4.162

Review 10.  New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Authors:  Paul G Richardson; Shaji Kumar; Jacob P Laubach; Claudia Paba-Prada; Neeraj Gupta; Deborah Berg; Helgi van de Velde; Philippe Moreau
Journal:  J Blood Med       Date:  2017-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.